TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
The Chinese biotech said the enrollment marks a key milestone for its advancing bile duct cancer treatment By Teri Yu Clinical-stage biotech firm TransThera Sciences (Nanjing) Inc. (2617.HK) said it…
